Shares of Allergy Therapeutics plc (LON:AGY – Get Free Report) reached a new 52-week high on Tuesday . The company traded as high as GBX 8 ($0.10) and last traded at GBX 7.70 ($0.09), with a volume of 230809 shares. The stock had previously closed at GBX 7.70 ($0.09).
Allergy Therapeutics Price Performance
The firm has a 50 day moving average of GBX 6.24 and a 200-day moving average of GBX 5.29. The company has a debt-to-equity ratio of 37.22, a current ratio of 1.40 and a quick ratio of 1.48. The stock has a market capitalization of £367.29 million, a P/E ratio of -128.33, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Read More
- Five stocks we like better than Allergy Therapeutics
- Dividend Payout Ratio Calculator
- SAP’s Strong Momentum: A Bullish Setup for Investors
- Basic Materials Stocks Investing
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- Consumer Discretionary Stocks Explained
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
